Latest Biotech News

UCB announced it will acquire Candid for $2.2B, placing a large bet on Candid’s antibody assets aimed at autoimmune diseases. The deal centers on a portfolio of bispecific and related biologic...

Rigel Pharmaceuticals published final data from its Phase 1/2 ARROW trial of pralsetinib (Gavreto) in metastatic RET fusion-positive NSCLC in the Journal of Clinical Oncology. The update adds 42...

Replimune’s RP1 oncolytic immunotherapy has faced additional regulatory setbacks after the FDA rejected the therapy twice, despite prior breakthrough-style emphasis in its clinical development....

Erasca shares fell after the company disclosed a patient death tied to an adverse event in a previously shared dose-escalation dataset for ERAS-0015. The disclosure surfaced in investor materials...

Four biotech IPOs raised $1.5B in April, the biggest monthly tally in more than five years, according to Renaissance Capital. The new listings included Hemab Therapeutics and Seaport Therapeutics,...

Researchers reported new immunology findings implicating CD44+ monocytes in bronchopulmonary dysplasia (BPD) in very premature infants. The work focuses on hyperinflammation in BPD, a chronic lung...

A research team reported that digital twins built from ex vivo human lung perfusion (EVLP) data can model therapeutic effects with high fidelity. Using a large clinical EVLP dataset, the...

Researchers published an economic evaluation in the British Journal of Cancer assessing whether adding AI to the UK breast screening pathway is cost-effective. The analysis compared AI-driven...

A technical piece on AI drug repurposing argued that performance bottlenecks often come from fragmented or inconsistent foundational data rather than insufficient model scale. The article...

Researchers reported in Science that AI helped create an engineered bacterium partially missing a universally used amino acid building block. The team used AI to propose alternatives to isoleucine...

Four biotech IPOs raised $1.5B in April, the biggest month in more than five years, according to Renaissance Capital. Hemab Therapeutics and Seaport Therapeutics joined the public markets with...

Rigel Pharmaceuticals published final 42-month follow-up from its Phase 1/2 ARROW study of pralsetinib (GAVRETO) in RET fusion-positive metastatic NSCLC in the Journal of Clinical Oncology. The...

The FDA twice declined to approve Replimune Group’s RP1, an oncolytic immunotherapy for melanoma previously granted breakthrough therapy status, raising fresh concerns for developers relying on...

UCB moved to expand its autoimmune pipeline by backing Ken Song’s T cell engager ambitions with a reported $2 billion bet on Candid, a company advancing T cell engager programs designed for...

Erasca’s shares sank 53% amid disclosure around a death connected to ERAS-0015’s treatment-related adverse event timeline in earlier data. The precision oncology company developing an oral pan-RAS...

Researchers used AI-guided design to partially eliminate isoleucine from proteins in an engineered Escherichia coli system by proposing structurally similar replacements across dozens of bacterial...

A study identifying CD44+ monocytes as drivers of inflammation in very premature infants advances mechanistic understanding of bronchopulmonary dysplasia (BPD), according to the report. The...

Work on bridging biomarker gaps for very low birth weight (VLBW) sepsis tests highlights ongoing unmet needs in neonatal diagnostics. Sepsis remains a leading cause of morbidity and mortality in...

A Nature Communications multicohort analysis links small-for-gestational-age constraints to long-term pulmonary impairments via axon guidance pathways. Investigators say the study provides “first...

A Karolinska Institutet-led study reported that low-dose endoxifen, an active metabolite of tamoxifen, can significantly reduce mammographic breast density with fewer side effects, with results...